Executive Summary
Medicare is on a path to covering TAVR for native aortic regurgitation, and the three societies that built the TAVR infrastructure just told CMS to do it with guardrails: registry-based evidence development, FDA-approved devices only, and an in-person evaluation by both an interventional cardiologist and a cardiac surgeon for every candidate (ACC/SCAI/STS joint letter). The asymmetry in the evidence is the whole story: roughly 1 million US patients have had TAVR for aortic stenosis versus real-world data on about 1,500 treated for native AR. That gap is why the societies asked for a coverage-with-evidence-development framework even as CMS has been stripping CED elsewhere, and it is why the ESC 2025 guideline still rates TAVI for AR as Class IIb for inoperable patients only. Expanded access arriving ahead of the outcome data tightens, rather than loosens, the case for mandatory heart team review.
- CMS expects to publish its proposed AR coverage decision by March 2027, following JenaValve Trilogy's first-ever FDA approval for severe symptomatic AR (Cardiovascular Business).
- A PARTNER 3 seven-year editorial frames lifetime valve strategy as reassurance plus residual uncertainty, not resolution (J Thorac Dis).
- Current evidence does not establish superiority of self-expanding over balloon-expandable valves in small annuli; pick the platform, not the dogma (Am J Cardiol).
- UK multicentre series reports TAVI implants deployed in the mitral position as off-label TMVR, abstract not yet available (Heart).
- Boston Scientific closed at $42.86, down 32.8% over six months and sitting at its 52-week low into an October 28 earnings print.
What to watch: the CMS proposed national coverage determination for TAVR in native AR, expected March 2027, and whether it carries a CED registry mandate.
Aortic Valve (TAVR/TAVI)
Aortic regurgitation is about to become a reimbursed transcatheter indication on roughly 0.15% of the evidence base that built the stenosis indication. The ACC/SCAI/STS letter supports coverage for symptomatic severe AR confirmed by echo or CMR, restricted to FDA-approved devices, with registry reporting. Set that against the guidelines: ESC 2025 gives TAVI for AR Class IIb, inoperable patients with suitable anatomy only. ACC/AHA 2020 does not address it at all. Surgery for symptomatic severe AR remains Class I in both documents, and ESC 2025 makes valve-sparing root replacement Class I in young patients. No randomized trial has tested TAVI against surgical AV repair or replacement in native AR, the same evidence gap that keeps surgery preferred in bicuspid stenosis under both guidelines. Until that trial exists, the surgeon-in-the-room requirement is the only check on indication creep.
Two supporting items. A narrative review of post-TAVI risk (Expert Rev Cardiovasc Ther, non-systematic) argues for prevention-first lifetime planning: CT-based sizing, conduction risk, coronary access, endocarditis pathways. And in small annuli, Sá and Kilic conclude the observational signal favoring self-expanding valves has not survived replication, with severe patient-prosthesis mismatch and pacemaker need as competing risks. SAVR with root enlargement remains the ESC-favored route when PPM is the dominant concern.
Mitral Valve (MitraClip, PASCAL, TMVR)
Operators are improvising mitral replacement with aortic hardware, and the field should say so plainly. A UK multicentre experience describes transcatheter mitral valve replacement using TAVI implants in the mitral position (Heart); no abstract is posted, so sample size, MAC burden, LVOT obstruction rates, and mortality are all unknown until the full text lands. Treat it as hypothesis-generating. ESC 2025 gives TMVI Class IIb for degenerative MS with annular calcification at experienced centres and nothing higher; surgical mitral replacement with annular debridement remains the comparator, with repair preferred (Class I) whenever a durable result is expected.
Separately, a JACC: Cardiovascular Imaging state-of-the-art review on arrhythmogenic mitral valve prolapse makes a point that cuts against procedural enthusiasm: correcting the regurgitation hemodynamically does not erase the arrhythmic substrate. Mitral annular disjunction, basal inferolateral curling, and late gadolinium enhancement persist. Surgical annuloplasty at least stabilizes the annulus; TEER does not. Phenotype before you clip. A single-case report of MitraClip "sandwiching" a posterior leaflet perforation under 3D MPR guidance (JACC Case Reports, N=1) is a technical curiosity, not an indication.
Surgical vs. Transcatheter Comparisons
No head-to-head trial reported today. The nearest thing is an editorial reading of seven years of PARTNER 3, which lands on reassurance with residual uncertainty: no durability divergence yet, but the cohort that matters most for lifetime management, patients under 65 with 20-plus years of expected valve exposure, is the cohort the trial never enrolled. That is precisely the gap ESC 2025 cited when it set SAVR as Class I below age 70 in low-risk patients and acknowledged that under-70s are poorly represented in the randomized data. ACC/AHA 2020 draws the SAVR line at 65 and hands 65 to 80 to shared decision-making. The five-year lower-risk meta-analysis showing a 20% mortality reduction with TAVR has been challenged on risk-stratification grounds, with the difference disappearing once intermediate-risk trials are excluded. Seven-year PARTNER 3 does not settle that argument. Ten-year data will.
Device & Technology
Embolic protection is being priced as a growth category on the assumption that TAVR volumes keep climbing into younger patients, per a market forecast to 2035. The clinical case is softer than the market case: PROTECTED TAVR did not reduce all-cause stroke, and both guideline bodies leave CEP as selective rather than routine. Forecasts built on procedure volume alone will overshoot if reimbursement follows the randomized data.
On the pulmonary side, speckle-tracking in 50 patients after transcatheter PVR showed RV free-wall longitudinal strain improving from -20.3% to -23.3% at six months with no change on postoperative day 1 (Pediatric Cardiology, single-centre, no surgical PVR comparator). The delayed recovery curve is the useful finding: judging RV response at discharge misclassifies these patients.
Regulatory & Policy
[NOTABLE] CMS initiated the native AR coverage review internally, not at a vendor's request, which signals intent rather than lobbying response. The societies asked for a coverage pathway that reuses existing TAVR program infrastructure while attaching a CED registry requirement (full letter). Note the inconsistency they are navigating: CMS recently eliminated CED for symptomatic severe AS while retaining it for asymptomatic TAVR. Reinstating it for AR, an indication with no randomized comparator against surgery and no long-term durability data in a regurgitant, often non-calcified annulus, is the minimum defensible position. Proposed decision expected March 2027.
Industry & Market
Edwards is working the access and indication flanks simultaneously: coverage of a pediatric valve approval as a potential catalyst, plus a 25-year milestone in Thailand framed around valve care access. Institutional positioning is following; Sivik Global Healthcare raised its EW stake. The AR coverage pathway is the bigger medium-term lever for the category, and it benefits JenaValve, a private company, first.
Financial Analysis
The structural heart tape is split. Edwards is up 9.6% over six months with the AR and pediatric indication stories both live, and trades at a forward P/E of 25.4 that already assumes indication expansion executes. Abbott, up 2.7%, carries a strong-buy consensus and a $120.72 target into an October 21 print; its structural franchise spans MitraClip and TriClip, and ESC 2025 handed both a guideline upgrade this year (TEER for ventricular secondary MR to Class I, transcatheter tricuspid to Class IIa) that US reimbursement has not yet matched. Medtronic sits at a 14.4 forward multiple, the cheapest large-cap exposure, with Evolut's small-annulus positioning now less differentiated given today's Am J Cardiol read that no platform has demonstrated superiority there. Boston Scientific is the outlier, down 32.8% and printing a 52-week low; nothing in today's sources explains it, and the October 28 call is where the structural heart segment either defends the multiple or does not.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $85.68, +$0.41 (+0.49%); 6-month change +9.57%
- Market cap $49.3B; trailing P/E 51.0, forward P/E 25.37; beta 0.86
- 52-week range $72.40 to $96.29; 5-day range $82.43 to $86.77
- Analyst target $101.96 (range $84 to $110, 26 analysts); consensus buy
- Next earnings November 4 (EPS est $0.74, revenue est $1.68B)
The AR coverage pathway and the pediatric valve approval are both access stories, not volume stories yet. A 51x trailing multiple prices in execution on indication expansion that CMS will not rule on until 2027.
Medtronic (MDT)
- Close $92.41, -$0.60 (-0.65%); 6-month change +6.68%
- Market cap $118.2B; trailing P/E 22.71, forward P/E 14.41; beta 0.57
- 52-week range $73.31 to $106.33
- Analyst target $104.40 (range $85 to $121, 25 analysts); consensus buy
- Next earnings November 17 (EPS est $1.33, revenue est $9.48B)
Evolut's supra-annular hemodynamics have been the small-annulus selling point. Today's evidence review removes that as a survival argument, leaving pacemaker rate as the counterweight.
Abbott (ABT)
- Close $102.42, -$0.19 (-0.19%); 6-month change +2.72%
- Market cap $178.4B; trailing P/E 33.04, forward P/E 16.88; beta 0.58
- 52-week range $81.97 to $132.03
- Analyst target $120.72 (range $103 to $135, 26 analysts); consensus strong buy
- Next earnings October 21 (EPS est $1.41, revenue est $12.99B)
Highest analyst conviction in the group. The structural heart question on the call is TriClip uptake against a US reimbursement environment that has not caught up to the ESC Class IIa.
Boston Scientific (BSX)
- Close $42.86, -$0.45 (-1.04%); 6-month change -32.84%
- Market cap $62.1B; trailing P/E 17.35, forward P/E 12.68; beta 0.57
- 52-week range $41.39 to $105.65, currently at the low
- Analyst target $59.55 (range $44 to $94, 29 analysts); consensus buy
- Next earnings October 28 (EPS est $0.75, revenue est $5.11B)
A 29-analyst target range spanning $44 to $94 is the market admitting it does not know what this business is worth. The ACURATE neo2 withdrawal and the Watchman trajectory are the structural variables to listen for.
Anteris Technologies (AVR.AX)
- Close A$9.11, -A$0.32 (-3.39%); 6-month change +7.81%
- Market cap $0.9B; forward P/E -4.20 (pre-revenue)
- 52-week range A$5.20 to A$15.47
- Single analyst target A$13.00
DurAVR's single-piece ADAPT tissue thesis is a durability bet, which is exactly the claim that needs 10-year data nobody has. Thin volume, wide swings.
Market outlook: the category's valuation spread now tracks indication breadth rather than procedure volume. Edwards and Abbott hold the expanding-indication franchises (AR, tricuspid, mitral), Medtronic holds the value case, and Boston Scientific is being repriced on something the sell side has not converged on. JenaValve, J Valve Technology, and Meril Life Sciences remain private; JenaValve is the direct beneficiary of the CMS AR pathway and is not investable through these tickers.
Clinical Trial Updates
COMBINE-INTERVENE has completed enrolment across 50 centres: 1,223 multivessel disease patients randomized to revascularization driven by severe ischemia (FFR ≤0.75) or OCT-detected vulnerable plaque regardless of ischemia, versus standard FFR ≤0.80 (EuroIntervention, NCT05333068). Primary endpoint is cardiac death, any MI, or clinically driven revascularization at 24 months. Relevant to this audience because PCI-before-TAVR decisions in patients with non-complex CAD lean on the same ischemia-only logic, and ESC 2025 lists non-complex CAD amenable to PCI as a TAVI-favoring factor.
EAPCI and ACVC published an updated consensus on temporary mechanical circulatory support in cardiogenic shock (European Heart Journal), emphasizing phenotype-driven device selection and shock teams. Routine VA-ECMO in AMI-shock has not improved survival. That matters for high-risk TAVR programs planning hemodynamic backup.
The next real inflection is the CMS proposed decision on native AR, due March 2027. It will answer whether US policy still requires evidence generation as the price of access, or whether speed to market has won. The societies asked for a registry. Whether CMS grants it sets the template for every transcatheter indication that arrives before its randomized data does.